The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus Infection
Open accessAbstract
UNLABELLED: Severe acute respiratory syndrome coronavirus (SARS-CoV) caused an acute human respiratory illness with high morbidity and mortality in 2002-2003. Several studies have demonstrated the role of neutralizing antibodies induced by the spike (S) glycoprotein in protecting susceptible hosts from lethal infection. However, the anti-SARS-CoV antibody response is short-lived in patients who have recovered from SARS, making it critical to develop additional vaccine strategies. SARS-CoV-specific memory CD8 T cells persisted for up to 6 years after SARS-CoV infection, a time at which memory B cells and antivirus antibodies were undetectable in individuals who had recovered from SARS. In this study, we assessed the ability of virus-specific memory CD8 T cells to mediate protection against infection in the absence of SARS-CoV-specific memory CD4 T or B cells. We demonstrate that memory CD8 T cells specific for a single immunodominant epitope (S436 or S525) substantially protected 8- to 10-month-old mice from lethal SARS-CoV infection. Intravenous immunization with peptide-loaded dendritic cells (DCs) followed by intranasal boosting with recombinant vaccinia virus (rVV) encoding S436 or S525 resulted in accumulation of virus-specific memory CD8 T cells in bronchoalveolar lavage fluid (BAL), lungs, and spleen. Upon challenge with a lethal dose of SARS-CoV, virus-specific memory CD8 T cells efficiently produced multiple effector cytokines (gamma interferon [IFN-γ], tumor necrosis factor alpha [TNF-α], and interleukin 2 [IL-2]) and cytolytic molecules (granzyme B) and reduced lung viral loads. Overall, our results show that SARS-CoV-specific memory CD8 T cells protect susceptible hosts from lethal SARS-CoV infection, but they also suggest that SARS-CoV-specific CD4 T cell and antibody responses are necessary for complete protection. IMPORTANCE: Virus-specific CD8 T cells are required for pathogen clearance following primary SARS-CoV infection. However, the role of SARS-CoV-specific memory CD8 T cells in mediating protection after SARS-CoV challenge has not been previously investigated. In this study, using a prime-boost immunization approach, we showed that virus-specific CD8 T cells protect susceptible 8- to 10-month-old mice from lethal SARS-CoV challenge. Thus, future vaccines against emerging coronaviruses should emphasize the generation of a memory CD8 T cell response for optimal protection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“anti-S T-cell responses to the related SARS- and MERS-CoVs contribute toward viral clearance in normal as well as aged mice infected with SARS- or MERS-CoV, respectively (43–45).”
From An Alphavirus -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates (2020) · cites this paper as [45]
Experimental — accuracy not yet measuredIn the citing paper
“Memory T cells, particularly those residing at the upper airways might limit disease severity and shorten the duration of disease by rapidly eliminating infected cells and coordinating the production of antibodies [67]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [67]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677
T-cell quality in memory and protection: implications for vaccine design
Seder, R. A., Darrah, P. A., & Roederer, M. (2008) · Nature reviews. Immunology · doi:10.1038/nri2274 · Cited by 1,565
Severe acute respiratory syndrome
Peiris, M. J. S., Guan, Y., & Yuen, K. (2004) · Nature Medicine · doi:10.1038/nm1143 · Cited by 1,157
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome
Kuiken, T., Fouchier, R. A. M., Schutten, M., Rimmelzwaan, G. F., van Amerongen, G., van Riel, D. A. J., Laman, J. D., de Jong, T., van Doornum, G., Lim, W. W. L., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13967-0 · Cited by 1,015
Koch's postulates fulfilled for SARS virus
Fouchier, R. A. M., Kuiken, T., Schutten, M., van Amerongen, G., van Doornum, G. J. J., van den Hoogen, B. G., Peiris, M. J. S., Lim, W. W. L., Stöhr, K., & Osterhaus, A. D. M. E. (2003) · Nature · doi:10.1038/423240a · Cited by 790
A decade after SARS: strategies for controlling emerging coronaviruses
Graham, R. L., Donaldson, E., & Baric, R. S. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro3143 · Cited by 689
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
Yang, Z.-Y., Kong, W., Huang, Y., Roberts, A., Murphy, B., Subbarao, K., & Nabel, G. (2004) · Nature · doi:10.1038/nature02463 · Cited by 688
Sensing and alarm function of resident memory CD8+ T cells
Schenkel, J., Fraser, K. A., Vezys, V., & Masopust, D. (2013) · Nature Immunology · doi:10.1038/ni.2568 · Cited by 648
Teijaro, J. R., Turner, D., Pham, Q., Wherry, E. J., Lefrançois, L., & Farber, D. L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1102243 · Cited by 641
Cited by
Sorted by citations
Items 401–416 of 416
Obesity and Acute Respiratory Distress Syndrome
Tharp, W. G., & Stapleton, R. D. (2024) · Respiratory medicine · doi:10.1007/978-3-031-52696-1_17
Labordiagnostik viraler Atemwegserkrankungen
Kriegshäuser, G., Passarge, M., & Schütz, B. (2024) · Springer eBooks · doi:10.1007/978-3-662-67508-3_9
Palmer, P., Fedosyuk, S., Parthasarathy, S., Holbrook, J. A., George, C. L., O’Reilly, L., Wiegand, L., Carnell, G., Heeney, J. L., & Vishwanath, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.14.648815
Krickeberg, N., Rammensee, H., & Schilbach, K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1676455
Qin, T., Shen, B., Li, E., Jin, S., Luo, R., Zhang, Y., Qi, J., Deng, X., Shi, Z., Wang, T., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22671338
Ward, D., Higgins, M., Phelan, J. E., Hibberd, M. L., Campino, S. G., & Clark, T. G. (2021) · Figshare · doi:10.6084/m9.figshare.13545656
Additional file 1 of Accelerated immune ageing is associated with COVID-19 disease severity
Lord, J. M., Veenith, T., Sullivan, J., Sharma‐Oates, A., Richter, A. G., Greening, N. J., McAuley, H., Evans, R. A., Moss, P. A. H., Moore, S. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26666446
Additional file 2 of Accelerated immune ageing is associated with COVID-19 disease severity
Lord, J. M., Veenith, T., Sullivan, J., Sharma‐Oates, A., Richter, A. G., Greening, N. J., McAuley, H., Evans, R. A., Moss, P. A. H., Moore, S. C., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26666449
Immunological Persistence and Risk of SARS-CoV-2 Reinfection: Insights and Implications
Kumar, S., & BASU, M. N. (2025) · Medical virology · doi:10.1007/978-981-95-1426-7_11
Clinical evidence on BCG vaccination and COVID-19 infection: A systematic review
Yadav, P., Singh, A., Kumari, M., Verma, S. K., & Singh, D. (2026) · Respiratory Investigation · doi:10.1016/j.resinv.2026.101422
Palmer, P., Fedosyuk, S., Parthasarathy, S., Holbrook, J. A., George, C. L., O’Reilly, L., Wiegand, L., Carnell, G., Heeney, J. L., & Vishwanath, S. (2026) · Cell Reports Methods · doi:10.1016/j.crmeth.2026.101508
“19 In coronaviruses, robust T cell responses have been associated with effective clearance of infections, 21,22 milder disease, 23 reduced transmission, 24 long-lasting immunity, 25 and decreased susceptibility to immune escape.”
Tiwarekar, V., Ebenig, A., Predota, Y., Schrauf, S., Hörner, C., Lange, M. V., Gadalla, M. R., Auste, A., Miskey, C., Muraleedharan, S., et al. (2026) · Journal of Virology · doi:10.1128/jvi.00644-26
“…MERS-CoV S protein-specific T cells, isolated splenocytes were cultivated in the presence of 10 μg/mL MERS-CoV S-derived peptide S1165 (Biosynthesis Inc., Lewisville, TX, USA [46]) or 10 μg/mL SIINFEKL control peptide (SIN) of ovalbumin (aa 257–264) (InvivoGen, San Diego, CA, USA), as appropriate.”
The Role of Human Viral Entry Receptor Mouse Models in Advancing Antiviral Antibodies and Vaccines
Zuo, N., Zheng, X., Ishaq, R., Ren, D., & Hu, A. (2026) · Vaccines · doi:10.3390/vaccines14070614
“SARS-CoV-specific memory CD8 T cells can protect against lethal challenge in mice, and SARS-CoV-2 epitope mapping in humans has defined immunodominance and immunoprevalence patterns in depth [98,99].”
Borgoyakova, M. B., Рудометов, А. П., Sharabrin, S. V., Starostina, E. V., Yakovlev, V. A., Tigeeva, E. V., Vahitov, D. I., Zaykovskaya, A. V., Орлова, Л. А., Kisakov, D. N., et al. (2026) · Biological Products Prevention Diagnosis Treatment · doi:10.30895/2221-996x-2026-26-3-287-298
Grifoni, A. (2026) · ImmPort · doi:10.21430/m37vglvr69
Metadata
- Authors
- Channappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K., & Perlman, S.
- Affiliations
- University of Iowa (US)
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2014-10
- Volume
- 88
- Issue
- 19
- Pages
- 11034-11044
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC4178831
- OpenAlex
- W2004583429
- Cited by
- 411
- References
- 53
- Citations by year
- 2026: 8 · 2025: 14 · 2024: 14 · 2023: 39 · 2022: 51 · 2021: 117 · 2020: 142 · 2019: 3 · 2018: 6 · 2017: 4 · 2016: 6 · 2015: 3 · 2014: 3
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Virology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (AI060699)
- National Institute of Allergy and Infectious Diseases (AI091322, R01AI091322, AI060699, P01AI060699)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK054759)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- SARS-CoV, memory CD8+ T cells, T cell immunity, immunodominant epitopes, spike protein, prime-boost vaccination, peptide-loaded dendritic cells, vaccinia virus vector, lung viral load, cytokine production, granzyme B
- MeSH terms
- Animals, Antibodies, Viral, Antigens, Viral, Dendritic Cells, Female, Humans, Immunity, Active, Immunity, Cellular, Immunization, Immunologic Memory, Peptides, CD4-Positive T-Lymphocytes, Gene Expression, Survival Analysis, CD8-Positive T-Lymphocytes, Epitopes, T-Lymphocyte, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus, Mice, Immunity, Humoral
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
